ALNY News and Press, Alnylam Pharmaceuticals Inc. From 09/29/22

Summary The key catalyst for Travere in the near term is the PDUFA date for sparsentan for the treatment of IgA nephropathy in early November. With a positive outcome anticipated, there might not be enough reward to hold the stock into the event. Given the recent slow launches...

Summary Shares of Alnylam surged last month after the company reported positive results from the APOLLO-B trial of Onpattro. In early September, Alnylam presented detailed data from the trial, showing a somewhat underwhelming difference between the placebo on the primary endpoint....

– Piyush Sharma to Serve as Chief Ethics and Compliance Officer and Evan Lippman as Chief Corporate Development and Strategy Officer – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of tw...

The European Commission (EC) approved Alnylam Pharmaceuticals' ( NASDAQ: ALNY ) RNAi therapy Amvuttra (vutrisiran) to treat hereditary transthyretin-mediated (hATTR) amyloidosis in adults patients with stage 1 or stage 2 polyneuropathy. In July, a panel of the Eur...

– AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHM...

– Series Will Culminate in a Virtual R&D Day on December 15, 2022 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 9 th annual series of “RNAi Roundtable” ...

Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers PR Newswire Target knockdown and safety results support continued clinical development Regeneron and Alnylam intend to initiate a Phase 2 s...

Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY...

– Company to Webcast Investor Event on September 30 th at 8:00 p.m. ET – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present additional data from the APOLLO-B Phase 3 study o...

Alnylam ( NASDAQ: ALNY ) has priced its previously announced private offering of $900M principal amount of 1.00% convertible senior notes due 2027. The initial purchasers are granted an option to purchase an additional $135.0M aggregate principal amount of the notes. ...